Biomarin Pharma
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Biomarin Pharma
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
/ 
Frequently asked questions
To buy Biomarin Pharma stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Biomarin Pharma by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Biomarin Pharma is BMRN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Biomarin Pharma has its primary listing on NASDAQ. You can trade Biomarin Pharma with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Biomarin Pharma is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Biomarin Pharma as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Biomarin Pharma.